Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2026-06-05 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a “2025 Annual General Meeting of Shareholders Resolution Announcement” by Shenzhen Haiwang Bioengineering Co., Ltd. It details the attendance, voting methods, agendas, and precise voting results for each resolution item at the shareholders’ meeting. This corresponds exactly to a Declaration of Voting Results announcement (code DVA).
2026-06-05 Chinese
关于提供财务资助的进展公告
Capital/Financing Update Classification · 65% confidence The document is a corporate announcement regarding the progress of providing financial assistance (“财务资助”) to its subsidiaries—detailing amounts advanced, risk controls, and cumulative balances. This is not a financial report, earnings release, or AGM material; it is an update on the company’s financing activities. Therefore it best fits the Capital/Financing Update category (CAP).
2026-06-05 Chinese
北京德恒（深圳）律师事务所关于深圳市海王生物股份有限公司2025年年度股东会的法律意见
Regulatory Filings Classification · 85% confidence The document is a law firm’s legal opinion letter regarding the convening and procedures of the company’s 2025 Annual General Meeting, including a certification of voting processes and results. It is an attestation by external lawyers rather than the substantive AGM materials themselves or a standalone voting results announcement by the company. Under the Certification Rule, such a legal opinion letter is classified as a general regulatory filing rather than an Annual Report, AGM materials, or Declaration of Voting Results category. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-06-05 Chinese
关于股票交易被实施其他风险警示相关事项的进展公告
Regulatory Filings Classification · 86% confidence The document is an exchange-mandated monthly progress update on remediation measures following a negative internal control audit opinion and the imposition of a risk warning under Shenzhen Stock Exchange listing rules. It is an ongoing compliance announcement rather than a standalone financial report, management change, dividend notice, or similar. It does not include substantive financial statements nor is it merely announcing the publication of a different report. This is best classified as a general regulatory announcement (fallback category).
2026-06-01 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 85% confidence The document is a public announcement by Shenzhen Stock Exchange-listed company ST Haiwang regarding abnormal stock trading fluctuations, including details of price movements, internal checks, and risk warnings. It is not an AGM material, financial report, management change, capital transaction, or any other specific category; rather, it is a general regulatory announcement under exchange rules. Therefore, it falls under the fallback category 'Regulatory Filings' (RNS).
2026-06-01 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 92% confidence The document is an official announcement by Shenzhen Haier Bio Engineering Co. regarding abnormal fluctuations in its stock trading over consecutive days, providing explanations and risk warnings as required by the Shenzhen Stock Exchange. It does not contain financial statements, meeting materials, voting results, or any specific form filings (e.g., 10-K, IR). It serves as a regulatory disclosure notice under exchange rules, fitting the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.